Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Adrien Foca"'
Autor:
Nadim Fares, Ourania M. Andrisani, Adrien Foca, Sagar M. Utturkar, Bingyu Yan, Philippe Merle, Nadia A. Lanman, Saravana Kumar Kailasam Mani, David Durantel, Majid Kazemian, Jiazeng Sun, Zhibin Cui
Publikováno v:
Theranostics
Rationale: RNA helicase DDX5 is downregulated during hepatitis B virus (HBV) replication, and poor prognosis HBV-related hepatocellular carcinoma (HCC). The aim of this study is to determine the mechanism and significance of DDX5 downregulation for H
Autor:
Thomas Lahlali, Ammen P. Dhillon, David Durantel, Adrien Foca, Amy S. Lee, Julie Lucifora, Anna Salvetti, Michel Rivoire
Publikováno v:
Antiviral Therapy
Antiviral Therapy, International Medical Press, 2020, 25 (3), pp.151-162. ⟨10.3851/IMP3361⟩
Antiviral Therapy, International Medical Press, 2020, 25 (3), pp.151-162. ⟨10.3851/IMP3361⟩
Background A link between HBV and PLK1 was clearly evidenced in HBV-driven carcinogenesis, and we have also recently shown that PLK1 is a proviral factor in the early phases of HBV infection. Moreover, we have shown that BI-2536, a small molecule PLK
Autor:
Benoît Lacombe, Julie Lucifora, Camille Ménard, Michelet Maud, Adrien Foca, Pauline Abrial, David Durantel, Patrice Andre, Christophe Ramière
Publikováno v:
Journal of Hepatology. 73:S834-S835
Autor:
Koen Vandyck, Thomas Lahlali, Fabien Zoulim, Frederik Pauwels, Jan Martin Berke, Adrien Foca, David Durantel, Karen Vergauwen
Publikováno v:
Antimicrobial agents and chemotherapy. 62(10)
The assembly of hepatitis B virus (HBV) core protein (HBc) into capsids represents a critical step of viral replication. HBc has multiple functions during the HBV life cycle, which makes it an attractive target for antiviral therapies. Capsid assembl
Virally encoded proteins have evolved to perform multiple functions, and the core protein (HBc) of the hepatitis B virus (HBV) is a perfect example. While HBc is the structural component of the viral nucleocapsid, additional novel functions for the n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3429ad6d30a6359ea590afc7c32da2a4
https://europepmc.org/articles/PMC5757518/
https://europepmc.org/articles/PMC5757518/
Autor:
David Durantel, Fouzia Amirache, François-Loïc Cosset, Adrien Foca, Thomas Lahlali, Pascal Jalaguier, Nathalie Isorce, Ahmed Diab, Fabien Zoulim, Lia N'Guyen, Floriane Fusil, Ourania M. Andrisani
Publikováno v:
Hepatology
Hepatology, Wiley-Blackwell, 2017, ⟨10.1002/hep.29236⟩
Hepatology, Wiley-Blackwell, 2017, ⟨10.1002/hep.29236⟩
Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal. Herein, we identified cellular serine/threonine Polo-like-kinase 1 (PLK1) as a